Researchers at the Rudolf Virchow Centre, University of Würzburg, discovered that vitamin B2 helps cancer cells resist a specific form of programmed cell death [1, 2].
This finding is significant because it identifies a metabolic shield that tumors use to survive. By understanding how riboflavin protects these cells, scientists may be able to dismantle that defense to make tumors more vulnerable to treatment [1, 3].
The study focused on ferroptosis, a process of programmed cell death that can suppress the growth of tumors [1, 3]. The researchers found that the metabolism of vitamin B2, also known as riboflavin, supports a cellular shield that prevents this process from occurring in cancer cells [1, 2].
To test whether this shield could be broken, the team used roseoflavin, a compound that mimics riboflavin [2]. The results indicated that blocking the vitamin B2 pathway with this compound made the cancer cells vulnerable to death [2, 3].
This discovery highlights the complex role of vitamins in cancer progression. While riboflavin is essential for healthy human function, its role in the metabolic pathways of a tumor can inadvertently protect the disease from the body's natural cell-death mechanisms [1, 3].
The research was detailed in a press release issued on May 15, 2026 [1].
“Vitamin B2 metabolism creates a protective shield that prevents ferroptosis.”
The identification of riboflavin's role in preventing ferroptosis suggests a potential shift in how metabolic inhibitors are used in oncology. If the 'shield' provided by vitamin B2 can be reliably neutralized using compounds like roseoflavin, it could lead to a new class of therapies that sensitize tumors to existing treatments or trigger cell death independently.
